Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

AuthorsConteduca, V.; Wetterskog, D.; Sharabiani, M. T. A.; Grande, E.; Fernández-Pérez, M. P.; Jayaram, A.; Castellano, D.; Romanel, A.; Lolli, C.; Casadio, V.; Gurioli, G.; Amadori, D.; Font, A.; Vázquez-Estévez, S.; González del Alba, Aránzazu; Mellado, B.; Fernández-Calvo, O.; Méndez-Vidal, M. J.; Climent, M. A.; Durán, Ignacio; Gallardo, Eduard; Rodríguez, A.; Santander, C.; Sáez, María Isabel; Puente, Javier; Gasi Tandefelt, D.; Wingate, A.; Dearnaley, D.; Demichelis, F.; de Giorgi, U.; González-Billalabeitia, E.; Attard, G.
KeywordsCastration-resistant prostate cancer
Androgen receptor
Plasma DNA
Issue Date3-May-2017
PublisherOxford University Press
CitationAnnals of Oncology 28(7): 1508-1516 (2017)
Abstract[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.
[Methods] We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial).
[Results] In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P < 0.001 and HR 3.81; 95% CI 2.28–6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08–4.39; P = 0.03, and HR 1.95; 95% CI 1.23–3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17–19.17; P = 0.035 and OR, 5.0; 95% CI 1.70–14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26–19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16–56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts.
[Conclusion] Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required.
[Clinical Trial number] NCT02288936 (PREMIERE trial).
Publisher version (URL)
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
mdx155.pdf374,93 kBAdobe PDFThumbnail
Show full item record
Review this work


checked on Nov 23, 2021

Google ScholarTM




WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.